NasdaqGS - Nasdaq Real Time Price USD

Enliven Therapeutics, Inc. (ELVN)

44.78 +1.09 (+2.49%)

At close: October 28 at 4:00:01 PM EDT

44.35 -0.43 (-0.96%)

After hours: October 28 at 4:46:52 PM EDT

Trade ELVN on Coinbase

Chart Range Bar

Advanced Chart

AlphaSpace Chart

Loading chart for ELVN

Previous Close 43.69
Open 43.69
Bid 32.18 x 200
Ask 55.94 x 200
Day's Range 43.39 - 44.94
52 Week Range 14.78 - 62.32
Volume 1,261,396
Avg. Volume 1,338,332
Market Cap (intraday) 3.281B
Beta (5Y Monthly) 0.34
PE Ratio (TTM) --
EPS (TTM) -1.67
Earnings Date (est.) Nov 11, 2026
Forward Dividend & Yield -- (0.00%)
1y Target Est 74.42
Zacks Rating Bearish

Enliven Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. Its clinical programs comprise ELVN-001, a small molecule kinase inhibitor which is in Phase 1 clinical trial to treat adults with chronic myeloid leukemia; and ELVN-002, a central nervous system (CNS) penetrant and irreversible human epidermal growth factor receptor 2 inhibitor that is in Phase 1 clinical trial for the treatment of non-small cell lung cancer (NSCLC) and other HER2 mutant tumors. The company was founded in 2019 and is headquartered in Boulder, Colorado.

www.enliventherapeutics.com

Full Time Employees

December 31

Fiscal Year Ends

Healthcare

Sector

Biotechnology

Industry

Trailing total returns as of 10/28/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .

YTD Return

ELVN

190.78%

S&P 500 (^GSPC)

13.13%

1-Year Return

ELVN

107.80%

S&P 500 (^GSPC)

12.38%

3-Year Return

ELVN

307.46%

S&P 500 (^GSPC)

88.08%

5-Year Return

ELVN

206.71%

S&P 500 (^GSPC)

68.48%

Earnings Per Share

gaap GAAP

nongaap Normalized

gaap GAAP

nongaap Normalized

Revenue vs. Earnings

yearly Annual

quarterly Quarterly

yearly Annual

quarterly Quarterly

Q2 FY26

Revenue --

Earnings -32.48M

Profit Margin 0.00%

FY25

FY26

-30M

-20M

-10M

0.0%

Analyst Price Targets

69.00

74.42 Average

44.78 Current

82.00 High

Analyst Recommendations

Strong Buy
Buy
Hold
Underperform
Sell

Latest Rating

Date 10/19/2026

Analyst HC Wainwright & Co.

Rating Action Maintains

Rating Buy

Price Action Raises

Price Target 65 -> 73

Valuation Measures

  
  
 Annual 

Market Cap
Enterprise Value
Trailing P/E
Forward P/E
PEG Ratio (current)
Price/Sales (ttm)
Price/Book (mrq)
Enterprise Value/Revenue
Enterprise Value/EBITDA

Financial Highlights

Profitability and Income Statement

Profit Margin

0.00%
Return on Assets (ttm)

-11.00%
Return on Equity (ttm)

-15.31%
Revenue (ttm)

--
Net Income Avi to Common (ttm)

-105.93M
Diluted EPS (ttm)

-1.67

Balance Sheet and Cash Flow

Total Cash (mrq)

895.16M
Total Debt/Equity (mrq)

0.17%
Levered Free Cash Flow (ttm)

-45.26M

SYRE Spyre Therapeutics, Inc.

99.75 +0.71%

EWTX Edgewise Therapeutics, Inc.

40.49 +2.43%

DNTH Dianthus Therapeutics, Inc.

82.31 +3.51%

MLYS Mineralys Therapeutics, Inc.

21.38 +1.18%

TYRA Tyra Biosciences, Inc.

21.75 +1.07%

U.S. markets open in 1h 42m

Enliven Therapeutics, Inc. (ELVN)

Trading disclosure

7.08%

-2.67%

4.19%

190.78%

107.80%

206.71%

-20.04%

Enliven Therapeutics, Inc. Overview Biotechnology / Healthcare

Full Time Employees

Fiscal Year Ends

Sector

Industry

Recent News

Performance Overview

YTD Return

1-Year Return

3-Year Return

5-Year Return

Earnings Trends

Earnings Per Share

Revenue vs. Earnings

Analyst Insights

Analyst Price Targets

Analyst Recommendations

Latest Rating

Statistics

Valuation Measures

Financial Highlights

Profitability and Income Statement

Balance Sheet and Cash Flow

Company Insights

Research Reports

People Also Watch